갈더마코리아

Galderma (SIX: GALD) is the emerging pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare & Therapeutic Dermatology. Since our foundation, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story.

Galderma, Swiss-based pharmaceutical company specializing in dermatology, delivers innovative solutions across the full spectrum of skin health. Operating through three business units; Injectable Aesthetics, Therapeutic Dermatology, and Dermatological Skincare. Galderma serves 90 countries, addressing concerns such as sensitive skin, wrinkles, acne, rosacea, etc.

In 2025, Galderma achieved net sales of approximately USD 4.41 billion, marking 9.3% year-on-year growth. The company drives growth through active clinical research, focusing on unmet needs in dermatology. Galderma has conducted over 770 clinical trials in around 30 countries to develop and deliver new products and technologies.